NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer

NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer

The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Patients with locoregional, pathologically high-risk HNSCC recur frequently despite adjuvant cisplatin–radiation therapy (CRT). Targeting PD1 may reverse immunosupp...

Full description

Bibliographic Details
Main Authors: Julie E. Bauman, Jonathan Harris, Ravindra Uppaluri, Min Yao, Robert L. Ferris, Josephine Chen, Richard C. Jordan, Nikhil P. Joshi, Srinivas Jujjuvaparu, Dukagjin M. Blakaj, Christina Henson, Jawad Sheqwara, Loren K. Mell, Neilayan Sen, David A. Clump, Madhur K. Garg, Emrullah Yilmaz, Pedro Torres-Saavedra, Quynh-Thu Le
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
head and neck cancer
pathologically high-risk
pembrolizumab
adjuvant
radiation therapy
cisplatin
Online Access:https://www.mdpi.com/2072-6694/13/12/2882

Internet

https://www.mdpi.com/2072-6694/13/12/2882

Similar Items